[Clinico-experimental correlation of the hypolipemic effects of mepartricin].
Mepartricin (SPA-S-160) fat-lowering effect was evaluated in several groups of rats, normal or with experimental hyperlipidemia. The substance had a normalizing action on the lipid levels, and in particular on the cholesterol component. These findings, compared to those obtained in preliminary clinical studies, confirm a mechanism of action, common to some other polyenes, selecting as molecular target the interaction with the cholesterol component.
D000818:Animals; D002784:Cholesterol / Q000097:blood; D005243:Feces / Q000032:analysis; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D050356:Lipid Metabolism; D008055:Lipids / Q000032:analysis; D008613:Mepartricin / Q000494:pharmacology / Q000627:therapeutic use*; D011090:Polyenes / Q000627:therapeutic use*; D051381:Rats; D014280:Triglycerides / Q000097:blood
D008055:Lipids; D011090:Polyenes; D014280:Triglycerides; D008613:Mepartricin; D002784:Cholesterol
Correlazione clinico-sperimentale degli effetti ipolipemizzanti della mepartricina.